Home LiteratureArticle Details
PMID: 12201864 Published · ppublish English Journal Article Review

Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment.

Journal of gastroenterology and hepatology ·Vol. 17 ·No. 10 ·2002-10-00 ·Pages 1056-63

Okuda K, Nakanuma Y, Miyazaki M

Abstract

Part 2 of this review discusses DNA damage in biliary epithelial cells in the development of cholangiocarcinoma, alterations in cell kinetics of biliary epithelial cells, biliary epithelial mitoinhibition, and apoptosis that includes the role of Bcl-2, transforming growth factor-beta, telomerase activities and deregulation of Ras and p53, cancer-associated antigens in cholangiocarcinoma, precancerous lesions, stroma formation and angiogenesis, cancer invasion, cell-cell and cell-matrix interactions, and the mechanism of evasion from immune surveillance. These discussions are followed briefly by treatments such as photodynamic therapy, and surgical approaches comparing resection and liver transplantation.

MeSH Terms
Apoptosis/genetics Bile Duct Neoplasms/genetics,pathology,surgery Cell Communication Cholangiocarcinoma/genetics,pathology,surgery DNA, Neoplasm/genetics Genes, bcl-2/genetics Genes, p53/genetics Humans Liver Transplantation/methods Mutation/genetics
Chemicals
DNA, Neoplasm
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Okuda Kunio
Department of Medicine, Chiba University School of Medicine, Chiba, Japan. okuda@med.m.chiba-u.ac.jp
Nakanuma Yasuni
Miyazaki Masaru
Article Info
Journal
Journal of gastroenterology and hepatology
Abbr.
J Gastroenterol Hepatol
ISSN
0815-9319
Published
2002-10-00
Pages
1056-63
Language
English
Region
Australia
NLM ID
8607909
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com